Genetic variation of cytochrome P450 oxidase and personalized medicine

Abstract

CLC Number:

R969.8

LV Pei-yu, YUAN Hong, ZHOU Hong-hao, OUYANG Dong-sheng. Genetic variation of cytochrome P450 oxidase and personalized medicine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1281-1287.

References 36

[1]	李晓宇, 刘皋林. CYP450酶特性及其应用研究进展[J]. 中国临床药理学与治疗学, 2008, 13(8): 942-946.
[2]	Lee SJ, Goldstein JA.Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests[J]. Pharmacogenomics, 2005, 6(4): 357-371.
[3]	Zochowska D, Wyzgal J, Paczek L.Impact of CYP3A41B and CYP3A53 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients[J]. Ann Transplant, 2012, 17(3): 36-44.
[4]	Lamba J, Hebert JM, Schuetz EG, et al.PharmGKB summary: very important pharmacogene information for CYP3A5[J]. Pharmacogenet Genomics, 2012, 22(7): 555-558.
[5]	Zuo X, Zhang W, Yuan H, et al.ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis[J]. Drug Metab Pharmacokinet, 2014,29(4):305-311.
[6]	Surendiran A, Pradhan SC, Agrawal A, et al.Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients[J]. Eur J Clin Pharmacol, 2011, 67(8): 797-801.
[7]	Xie HG, Prasad HC, Kim RB, et al.CYP2C9 allelic variants: ethnic distribution and functional significance[J]. Adv Drug Deliv Rev, 2002, 54(10): 1257-1270.
[8]	Garcia-Martin E, Martinez C, Tabares B, et al.Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms[J]. Clin Pharmacol Ther, 2004, 76(2): 119-127.
[9]	Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J]. Clin Pharmacol Ther, 2006, 79(1): 103-113.
[10]	Huezo-Diaz P, Perroud N, Spencer EP, et al.CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP[J]. J Psychopharmacol, 2012, 26(3): 398-407.
[11]	Andersson T, Flockhart DA, Goldstein DB, et al.Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests[J]. Clin Pharmacol Ther, 2005, 78(6): 559-581.
[12]	Raimundo S, Toscano C, Klein K, et al.A novel intronic mutation, 2988G> A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects[J]. Clin Pharmacol Ther, 2004, 76(2): 128-138.
[13]	Toscano C, Klein K, Blievernicht J, et al.Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events[J]. Pharmacogenet Genomics, 2006, 16(10): 755-766.
[14]	Ghotbi R, Christensen M, Roh HK, et al.Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans[J]. Eur J Clin Pharmacol, 2007, 63(6): 537-546.
[15]	Zhou H, Josephy PD, Kim D, et al.Functional characterization of four allelic variants of human cytochrome P450 1A2[J]. Arch Biochem Biophys, 2004, 422(1): 23-30.
[16]	Ingelman-Sundberg M, Sim SC, Gomez A, et al.Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3): 496-526.
[17]	Di Iulio J, Fayet A, Arab-Alameddine M, et al.In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function[J]. Pharmacogenet Genomics, 2009, 19(4): 300-309.
[18]	Mwenifumbo JC, Tyndale RF.Genetic variability in CYP2A6 and the pharmacokinetics of nicotine[J]. Pharmacogenomics, 2007, 8(10): 1385-1402.
[19]	Hofmann MH, Blievernicht JK, Klein K, et al.Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver[J]. J Pharmacol Exp Ther, 2008, 325(1): 284-292.
[20]	Hwang IC, Park JY, Ahn HY, et al.Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele[J]. Clin Chim Acta, 2014, 428(3): 77-81.
[21]	Johnstone E, Benowitz N, Cargill A, et al.Determinants of the rate of nicotine metabolism and effects on smoking behavior[J]. Clin Pharmacol Ther, 2006, 80(4): 319-330.
[22]	Klein K, Lang T, Saussele T, et al.Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz[J]. Pharmacogenet Genomics, 2005, 15(12): 861-873.
[23]	Klein TE, Altman RB, Eriksson N, et al.International warfarin pharmacogenetics consortium, estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360(4): 753-764.
[24]	Huang SW, Chen HS, Wang XQ, et al.Validation of VKORC1 and CYP2C9 genotypes on inter individual warfarin maintenance dose: a prospective study in Chinese patients[J]. Pharmacogenet Genomics, 2009, 19(3): 226-234.
[25]	Brauch H, Schroth W, Eichelbaum M, et al.Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer[J]. Breast Care,2008,3(1): 43-50.
[26]	Molanaei H, Carrero JJ, Heimbürger O, et al.Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease[J]. Eur J Clin Pharmacol, 2010, 66(3): 269-273.
[27]	Kirchheiner J, Schmidt H, Tzvetkov M, et al.Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication[J]. Pharmacogenomics J, 2007, 7(4): 257-265.
[28]	Ferreirós N, Dresen S, Hermanns-Clausen M, et al.Fatal and severe codeine intoxication in 3-year-old twins-interpretation of drug and metabolite concentrations[J]. Int J Legal Med, 2009, 123(5): 387-394.
[29]	Twardowschy CA, Werneck LC, Scola RH, et al.The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy[J]. Seizure, 2013, 22(3): 194-197.
[30]	Lee HW, Lim M, Lee J, et al.Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics[J]. J Clin Pharm Ther, 2012, 37(1): 105-111.
[31]	Food and Drug Administration. Guidance for industry: pharmacogenomic data submissions [A]. Department of Health and Human Services, FDA, 2005.
[32]	US Food and Drug Administration. Guidance for industry: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories [A]. Rockville: FDA, 2008.
[33]	Committee for Medicinal Products for Human Use. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products Draft [A]. European Medicines Agency, 2010.
[34]	US Food and Drug Administration. Guidance for industry drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations [A]. Food and Drug Administration: Rockville, MD, 2012.
[35]	US Department of Health and Human Services, FDA C, CBER C. Guidance for industry: clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling [A]. 2013.
[36]	Huang SM, Temple R. Is this the drug or dose for you: impact and consideration of ethnic factors in global drug development, regulatory review,clinical practice [J]. Clin Pharmacol Ther, 2008, 84(3): 287-295.本文编辑:储冀汝

Genetic variation of cytochrome P450 oxidase and personalized medicine

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 36

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[5]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[6]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[7]	SUN Yuanyuan, DENG Kunhong, WANG Siyi, KUANG Yun, ZOU Chan, GUO Chengxian, HE Qingnan, LIU Helin, YANG Guoping. Design and implementation of electronic identity application for gene-directed personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 274-280.
[8]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[9]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[10]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[11]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[12]	. Research Progress of Pharmacogenomics of Dabigatran Etexilate and Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1200-1207.
[13]	WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48.
[14]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[15]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.